{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:14:58Z","timestamp":1794860098466,"version":"4.9.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,1,29]]},"DOI":"10.1001\/jama.2018.20045","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T03:43:09Z","timestamp":1548819789000},"page":"364","source":"Crossref","is-referenced-by-count":659,"title":["Association of Triglyceride-Lowering <i>LPL<\/i> Variants and LDL-C\u2013Lowering <i>LDLR<\/i> Variants With Risk of Coronary Heart Disease"],"prefix":"10.1001","volume":"321","author":[{"given":"Brian A.","family":"Ference","sequence":"first","affiliation":[{"name":"Centre for Naturally Randomized Trials, University of Cambridge, Cambridge, United Kingdom"},{"name":"Institute for Advanced Studies, University of Bristol, Bristol, United Kingdom"},{"name":"MRC\/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Irving Institute for Clinical and Translational Research, Columbia University Vagelos College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Chapman","sequence":"additional","affiliation":[{"name":"National Institute for Health and Medical Research (INSERM), Pitie-Salpetriere University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Packard","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Oliver-Williams","sequence":"additional","affiliation":[{"name":"MRC\/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Wood","sequence":"additional","affiliation":[{"name":"MRC\/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Butterworth","sequence":"additional","affiliation":[{"name":"MRC\/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Di Angelantonio","sequence":"additional","affiliation":[{"name":"MRC\/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Danesh","sequence":"additional","affiliation":[{"name":"MRC\/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Cardiovascular Research Centre, University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan, Multimedica IRCCS, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"39","key":"joi180149r1","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias.","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"joi180149r2","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"joi180149r3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"joi180149r4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"32","key":"joi180149r5","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: 1, Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"joi180149r6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease.","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"joi180149r7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia.","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"joi180149r8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia.","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"joi180149r9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1161\/01.CIR.96.6.1737","article-title":"Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease.","volume":"96","author":"Nordestgaard","year":"1997","journal-title":"Circulation"},{"issue":"1","key":"joi180149r10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"joi180149r11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease.","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"joi180149r12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease.","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"joi180149r13","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease.","volume":"374","author":"Stitziel","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"joi180149r14","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"issue":"10","key":"joi180149r15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/ng1007-1181","article-title":"The NCBI dbGaP database of genotypes and phenotypes.","volume":"39","author":"Mailman","year":"2007","journal-title":"Nat Genet"},{"issue":"10","key":"joi180149r16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1000 genomes-based genome-wide association meta-analysis of coronary artery disease.","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"issue":"11","key":"joi180149r17","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels.","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"joi180149r18","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in &gt;300,000 individuals.","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"11","key":"joi180149r19","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/sim.v35.11","article-title":"Combining information on multiple instrumental variables in mendelian randomization: comparison of allele score and summarized data methods.","volume":"35","author":"Burgess","year":"2016","journal-title":"Stat Med"},{"issue":"5","key":"joi180149r20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/eurheartj\/ehx462","article-title":"How to use mendelian randomization to anticipate the results of randomized trials.","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"issue":"15","key":"joi180149r21","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 \u00d7 2 factorial mendelian randomization study.","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"joi180149r22","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes.","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"joi180149r23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk.","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"joi180149r24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.","volume":"27","author":"Bor\u00e9n","year":"2016","journal-title":"Curr Opin Lipidol"},{"issue":"9943","key":"joi180149r25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease.","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"joi180149r26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1073\/pnas.77.1.604","article-title":"Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].","volume":"77","author":"Sniderman","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"joi180149r27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease.","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9726","key":"joi180149r28","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"20","key":"joi180149r29","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease.","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"6","key":"joi180149r30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"joi180149r31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.","volume":"102","author":"Bezafibrate Infarction Prevention (BIP) Study","year":"2000","journal-title":"Circulation"},{"issue":"9500","key":"joi180149r32","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"joi180149r33","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"25","key":"joi180149r34","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis.","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"9567","key":"joi180149r35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"joi180149r36","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","author":"Bhatt","journal-title":"N Engl J Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2722770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T03:43:11Z","timestamp":1548819791000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2018.20045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,1,29]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2018.20045","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,29]]}}}